Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in
adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary
hyperoxaluria